Company Dossier · Health Care
Labcorp
- S&P 500
- Russell 1000
What Labcorp is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $14.3 billion, up 6.5% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.16 billion, down 7.9% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.48 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.45 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 30, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 7 outlook figures raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 24, 2026): 0 risk factors added, 2 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $3.3 million on the open market.SEC Form 4
- 1,050 institutional managers reported a position at June 30, 2026 (+27 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 53 (79 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 3 — latest OSHA inspection, Sep 15, 2026 →
Company Posture
How Company Posture is measured →What Labcorp is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending66th pct
- Debt raised—
- Buybacks vs capex68th pct
- Hiring filings93rd pct
- Deals and private raises43rd pct
- Patent publications11th pct
Confident ↔ Hedging
Confident
- Call sentiment81st pct
- Call confidence84th pct
- Guidance changes94th pct
- Risk factors added84th pct
- Insider open-market trades44th pct
- + Guidance changes
- + Call sentiment
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver47th pct
- Stress filings48th pct
Credit
How these are built →Labcorp's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$5.9B
- Due within a year $0.0B
- Longer term $5.9B
- Default point $3.0B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Sep 16, 2024 | $650M | 4.350% | 2030 (6y) | +95bp | 4.364% |
| Sep 16, 2024 | $500M | 4.550% | 2032 (8y) | +110bp | 4.612% |
| Sep 16, 2024 | $850M | 4.800% | 2034 (10y) | +120bp | 4.831% |
From the pricing term sheets Labcorp filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (KELLEY DRYE & WARREN LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 12, 2026LobbyingLobbying report (LABORATORY CORPORATION OF AMERICA HOLDINGS)third_quarter 2026 · $0.3 million
- Sep 15, 2026Risk event
- Sep 9, 2026Risk event
- Sep 2, 2026Risk event
- Sep 1, 2026Patent
- Aug 18, 2026Patent
- Aug 14, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (PARKER, POE, ADAMS & BERNSTEIN LLP)second_quarter 2026 · $0.0 million
- Jul 20, 2026LobbyingLobbying report (KELLEY DRYE & WARREN LLP)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)second_quarter 2026 · $0.1 million
- Jul 14, 2026LobbyingLobbying report (LABORATORY CORPORATION OF AMERICA HOLDINGS)second_quarter 2026 · $0.3 million
- May 26, 20268-KShareholder vote resultsItem 5.07
- Apr 20, 2026LobbyingLobbying report (PARKER, POE, ADAMS & BERNSTEIN LLP)first_quarter 2026 · $0.0 million
- Mar 20, 20268-KMaterial agreement signedItem 1.01
- Feb 24, 202610-KAnnual report (10-K)0 risk factors added, 2 removed
- Feb 9, 20268-KDirector or officer changeItem 5.02
- Jan 29, 20268-KMaterial agreement signedItem 1.01
- Dec 15, 20258-KDirector or officer changeItem 5.02
- Dec 10, 20258-KDirector or officer changeItem 5.02
- Nov 24, 20258-KDirector or officer changeItem 5.02
- Jun 27, 20258-KMaterial agreement signedItem 1.01
- May 20, 20258-KDirector or officer changeItem 5.02
- May 20, 20258-KShareholder vote resultsItem 5.07
- Feb 25, 202510-KAnnual report (10-K)1 risk factors added, 0 removed
- Jan 31, 20258-KMaterial agreement signedItem 1.01
- Nov 19, 20248-KDirector or officer changeItem 5.02
- Feb 26, 202410-KAnnual report (10-K)5 risk factors added, 3 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| BrightSpring Health Services BTSG | $14.4B | $0.4B | Jun 30, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |
| Henry Schein HSIC | $13.6B | $0.6B | Jun 27, 2026 |